Apr 23, 2025
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr 16, 2025
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
Mar 26, 2025
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Mar 04, 2025
Viking Therapeutics to Participate at Upcoming Investor Conferences
Jan 29, 2025
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
Jan 08, 2025
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Jan 06, 2025
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Nov 19, 2024
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Oct 16, 2024
Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
Oct 09, 2024
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Jul 24, 2024
Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 17, 2024
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
Jun 24, 2024
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
May 30, 2024
Viking Therapeutics to Participate at Upcoming Investor Conferences
Apr 17, 2024
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Mar 26, 2024
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Feb 28, 2024
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
Feb 27, 2024
Viking Therapeutics Announces Proposed Public Offering of Common Stock
Feb 10, 2021
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021
Jan 06, 2021
Viking Therapeutics Announces Senior Management Team Appointments